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Differential Dynamics of HIV Infection in Humanized MISTRG
versus MITRG Mice
Sandra Ivic,*,1 Mary-Aude Rochat,*,1 Duo Li,* Annette Audige´,* Erika Schlaepfer,* Christian Mu¨nz,† Markus G. Manz,‡ and
Roberto F. Speck*
*Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland; †Viral
Immunobiology, Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland; and ‡Department of Hematology, University
Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
ABSTRACT
Humanized mice are a powerful tool to study HIV in vivo. The recently generated mouse strains MITRG and MISTRG, which differ
in human SIRPa expression, support an improved human myeloid lineage development from human hematopoietic stem and
progenitor cells. The rationale of the study was the characterization of the two mouse strains during an HIV infection with CCR5- and
CXCR4-tropic viruses. Upon HIV infection, we observed HIV dissemination and sustained viral load over 20 wk in peripheral blood in
both reconstituted mouse strains. However, HIV RNA levels were significantly lower in MITRG mice compared with MISTRG mice
during the first 8 wk postinfection. HIV-infected MISTRG mice showed lymphocyte activation and changes in lymphocyte subsets in
blood and spleen, recapitulating hallmarks of HIV infection in humans. Depletion of murine tissue-resident macrophages in MITRG
mice led to significantly elevated viral loads, and lymphocyte levels were similar to those in HIV-infected MISTRG mice. Depletion of
CD8+ T cells in MISTRG mice before HIV infection resulted in substantially decreased CD4+ T cell levels, indicating functionality of
human CD8+ T cells; depletion of CD4+CD8+ thymocytes may have contributed, in part, to the latter finding. In summary, MITRG and
MISTRG mice represent novel HIV mouse models, despite differential HIV dynamics. ImmunoHorizons, 2017, 1: 162–175.
INTRODUCTION
Humanized mice (hu mice) have become a valuable tool for
studyinghumanhematopoiesis in health anddisease (1). In the last
two decades, diﬀerent knockouts (i.e., Rag1/22/2 and Pkrdc2/2)
have made mice more receptive to accepting human xenografts.
NOD-SCIDgc2/2 (NSG), NOD-SCID truncated gc (NOG), NOD
Rag12/2gc2/2 (NRG), and Rag22/2gc2/2 mice are the most
commonlyusedmouse strains forhumanization (2–4). In themid-
2000s, transplantation of umbilical cord blood–derived CD34+
hematopoietic stem and progenitor cells (HSPCs) into irradiated
newborn pups by intrahepatic (4) or i.v. injection (5) was tested
and resulted in higher levels of multilineage hematopoiesis than
the transplantation of human CD34+ cells into adult mice (6).
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Notably, NRG and NSG mice support better engraftment than
Rag22/2gc2/2 mice (6, 7). The rather modest engraftment in
Rag22/2gc2/2mice is explainedby the inadequate “don’t-eat-me”
signal that human cells transmit to murine macrophages. This
signal relies on the proper interaction of the ubiquitously ex-
pressed human CD47 and SIRPa on myeloid-monocytic cells.
Indeed, mice on a NOD background have a SIRPa allele that
eﬃciently recognizes humanCD47 and, thus, provides themurine
macrophages with the corresponding inhibitory signal (8).
To improve xenograft acceptance in hu mice with a missing
CD47–SIRPa interaction, transgenic expression of human SIRPa
(9), murine CD47 expression on human cells by lentiviral-
mediated gene transfer (10), or more recently, knockout ofmurine
CD47 (11) have been reported. In fact, the SIRPa–CD47 axis leads
to decreased engraftment of human acute leukemia stem cells in
hu mice on the NOD background (12).
The supply of human cytokines is critical for engraftment and
subsequent multilineage hematopoiesis in hu mice. Several hu-
man and mouse cytokines were reported to support immune cell
homeostasis in both species (13, 14), but human cells remain poorly
reactive to somemurinecytokines as a resultof their lowhomology
(15). Historically, the injection of various cytokines (e.g., IL-3,
SCF,GM-CSF)was used toboost humancell engraftment (16–18).
In addition, injection of cytokines was reported to enhance the
engraftment of distinct populations, such as NK cells, T cells, and
plasmacytoid dendritic cells (19–22). To overcome the need for
human cytokine administration, which, in general, does not
provide physiological levels, human cytokine knock-in strains of
immunodeﬁcient mice were engineered. Thus, various knock-in
mice of the Rag22/2gc2/2 strain were created, bearing human
TPO (14), GM-CSF/IL-3 (23), and M-CSF (14).
Two novel humanized mouse models were recently reported
(24) that combine the knock-in transgenes of a number of hu-
man cytokines (i.e., human M-CSF, IL-3, TPO, and GM-CSF) in
Rag22/2gc2/2 mice on a mixed Balb/c 3 129 background. The
mouse strain was namedMITRG. The second one, MISTRG, also
expresses the human SIRPa through a bacterial artiﬁcial chro-
mosome (9). MITRG and MISTRG mice support better human
myeloid cell engraftment than the currentgold standardNSGmice
and closely mirror the human hematopoietic proﬁle (24). In ad-
dition to the eﬃcient engraftment of cord blood–derived CD34+,
MISTRGmice showsuperiorengraftmentofmobilizedperipheral
bloodCD34+cells andmyeloid lineagedevelopment incomparison
with other mouse strains (25).
HIV is ahuman-speciﬁc virus.Humiceﬁll the long-neededgap
for conducting in vivo HIV research. Most HIV studies in humice
were done with humanized Rag22/2gc2/2 (26, 27), NOG (28), or
NSG (29)mice.Humicehave beenused to studyHIVpathogenesis
(30–32) and to explore novel therapeutic modalities (33, 34),
including gene engineering of an HIV-resistant immune system
(35, 36). Naturally, HIV research beneﬁts from the ongoing eﬀorts
to improvehumanization inmice.Thus, theaimof this studywas to
explore the value of MITRG andMISTRGmice for studying HIV.
The innate immune systemplays an important role duringHIV
infection.With thedevelopmentofMITRGandMISTRGmice,we
now have the opportunity to study these interactions in a small
animal model with a relatively prominent myeloid system. Specif-
ically, we aimed to characterize some aspects of acute and asymp-
tomatic HIV infection, to monitor the diﬀerential dynamics of
diverse cell types, and to explore whether the absence of human
SIRPawould inﬂuence viral replication in humanizedMITRGmice.
MATERIALS AND METHODS
Generation of hu mice
Humanized MISTRG and MITRG mice were generated essen-
tially as described (24). In brief, newborn MISTRG and MITRG
mice were injected intrahepatically with 2.03 105 CD34+ HSPCs
derived from umbilical cord blood within the ﬁrst 3 d after birth.
MISTRG and MITRG mice were bred and maintained in
individual ventilated cages and were fed autoclaved food and
water. Mice were monitored weekly for symptoms or signs of
adverse events, according to a standard score sheet. Engraftment
was checked in peripheral blood at 9–10 wk of age, and animals
with an engraftment . 5% human CD45+ (hCD45+) cells in
peripheral blood were used for experiments.
Virus production and infection
Viral stocks were obtained by polyethylenimine-mediated trans-
fection (Polysciences) of HEK293T cells (American Type Culture
Collection, Manassas, VA) with p–YU-2 or p–NL4-3 (provided
through the National Institutes of Health AIDS Research and
Reference Reagent Program). At 48 h after transfection, virus was
harvested, ﬁltered (0.22mm), and frozen at280°C until use. Viral
titers were determined as described (37). Brieﬂy, 50% tissue
culture infectious dose (TCID50) was determined by infecting
humanCD8+Tcell–depletedPBMCs fromthreehealthydonors that
were stimulated by the addition of IL-2, PHA, and anti-CD3 beads
(Dynal 11131D; Life Technologies). Mice were infected i.p. with HIV
YU-2 or NL4-3 at 200,000 TCID50 per mouse. HIV RNA plasma
levels were measured by RT-PCR (AmpliPrep/COBAS TaqMan
HIV-1 Test; Roche) at diﬀerent time points postinfection (p.i.).
CD34+ cell isolation from umbilical cord blood
HSPCs were isolated from human cord blood with anti-CD34
immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many)withayieldof0.5to43106HSPCs(purity$90%).HSPCsand
“nontargeted” fractionswerestored frozen in liquidnitrogenuntiluse.
Immunophenotypic analysis of blood and organ cells
The following human cell surface markers were used for
immunophenotyping of peripheral blood and splenocytes: CD45,
CD33, CD3, CD16, CD14, CD19, NKp46, CD4, CD8, HLA-DR,
CD38, CD11b, CD68, and CD163 and murine CD45, CD11b, Ly6C,
F4/80, and CD68 (all Abs were purchased from BioLegend, BD
Biosciences, and Beckman Coulter). Washing and reagent dilu-
tions were done with PBS or with FACS buﬀer (PBS containing
2% FBS and 0.05% sodium azide). Before acquisition, cells were
ﬁxed with 1% paraformaldehyde (Sigma). All acquisitions were
performed on a Cyan ADP (Beckman Coulter) ﬂow cytometer.
https://doi.org/10.4049/immunohorizons.1700042
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Data were analyzed with FlowJo 10 software (TreeStar, Ashland,
OR). Cellular debris and dead cells were excluded by their light-
scattering characteristics or with live/dead ﬁxable stain (Zombie
NIR; BioLegend).
Mononuclear phagocytic cell and CD8+ T cell depletion
Mice were treated i.p. with clodronate liposomes (CLDs; http://
www.clodronateliposomes.org; 1 mg/20 g bodyweight) at 9 wk of
age, followed byHIV YU-2 infection 48 h later. The maintenance
dosewas 0.5mg/20 g bodyweight onceweekly during the course
of the experiment. CD8+ T cell depletion was accomplished as
described (38). Brieﬂy, 50mg of anti-CD8+ T cell Ab OKT8 (Bio X
Cell)was administered i.p. on three consecutive days, followed by
HIV YU-2 infection. CD8+ T cell depletion was maintained by
repeating the procedure every 2 wk, and the depletion was
monitored in the peripheral blood.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6
(GraphPad). Data were subjected to an unpaired Mann–Whitney
U test, Kruskal–Wallis test, or Spearman correlation, as indicated
in the ﬁgure legends. The obtained p values were considered
signiﬁcant at p, 0.05.
Study approval
All animal experiments aswell as procurement of humancordblood
wereapprovedbyethical committeesof theUniversityofZurichand
theFederalVeterinaryDepartment.All animal experimentationwas
approved by the cantonal veterinary oﬃce Zurich (#93/2014). The
experiments were conducted according to local guidelines and the
Swiss animal protection law. Human cord blood was collected with
informed written consent of the parents.
RESULTS
Engraftment levels of nonirradiated MISTRG and MITRG mice
Hu MISTRG and MITRG mice with an engraftment . 60%, as
assessedbyperipheral bloodstaining for thepan-human leukocyte
marker CD45, are at risk for developing anemia over a short
time period as the result of ineﬃcient formation of human
RBCs and concomitant phagocytosis of mouse RBCs by human
macrophages (24). Omitting irradiation prior to transplanta-
tion of CD34+ human HSPCs resulted in reduced engraftment,
but it decreased the incidence of anemia. Because we opted
for an extended period of experimentation, we transplanted
without preconditioning and obtained blood engraftment of
hCD45+ cells of 31.676 2.94%and 16.536 1.94% (mean6 SEM,
p # 0.001) in MISTRG and MITRG mice, respectively, at 9 wk
of age (Fig. 1A).
We also observed diﬀerences in human lymphoid andmyeloid
cell populations in the blood of MISTRG and MITRG mice (Fig.
1B). All immune cell populations had signiﬁcantly higher re-
constitution levels inMISTRGmice than inMITRGmice,with the
exceptionofCD19+Bcells. Thediﬀerencesweremost pronounced
forCD3+Tcells (20.3962.83%versus 3.6860.61%,mean6SEM,
p, 0.0001) and CD33+myeloid cells (11.026 1.07% versus 4.406
0.52%, mean6 SEM, p, 0.0001).
Sustained HIV YU-2 infection in MISTRG and MITRG mice
We infected mice with the CCR5-tropic HIV-1 strain YU-2. Four
weeks p.i., HIV RNA copy numbers in the peripheral blood were
4.223 1056 1.033 105 per milliliter inMISTRGmice and 7.973
1046 4.653 104 per milliliter inMITRGmice (mean6 SEM, p,
0.0001) (Fig. 2A). Intriguingly, MISTRG mice had a viral peak at
8 wk p.i., andMITRGmice showed a progressive increase in HIV
copynumber toward the levels observed inMISTRGmice at 16wk
p.i. We noticed substantial diﬀerences in the percentages of CD3+
T cells between the groups (Fig. 2B). Initially, in MISTRG mice,
18.42 6 3.17% of total hCD45+ cells were CD3+ T cells, and their
frequency progressively increased to 84.10 6 8.65% in the
peripheral blood during the course of infection (Fig. 2B). In
contrast, MITRG mice had low levels (2.74 6 0.55%) at baseline,
increasing up to 37.60 6 9.28% at 20 wk p.i., which remained
signiﬁcantly below the CD3+ T cell frequency in MISTRG mice.
Within the CD3+ T cell population, CD4+ T cells inMISTRGmice
expandedup toweek8p.i.,whenHIVreplicationpeaked, and then
FIGURE 1. Efficient engraftment of nonirradiated MISTRG and MITRG mice at 9 wk of age.
Newborn MISTRG and MITRG mice were transplanted with umbilical cord blood–derived CD34+ HSPCs without irradiation. (A) Blood engraftment
of 9-wk-old MISTRG (n = 53) and MITRG (n = 47) mice. (B) Percentages of different cell populations of lymphoid and myeloid lineages gated on
hCD45+ cells. All data are mean 6 SEM. ***p # 0.001, two-tailed Mann–Whitney U test.
https://doi.org/10.4049/immunohorizons.1700042
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declined (Supplemental Fig. 1). In contrast, levels of CD8+ T cells
constantly increased (Supplemental Fig. 1).
HIVinfectionpromotes immuneactivationofTcells. InMISTRG
mice, we observed a positive correlation between the viral load in the
plasma andCD38+HLA-DR+CD4+T cells (Fig. 2C) andCD8+T cells
(Fig. 2D) in the blood at week 4 p.i.. These analyses were not
conclusive inMITRGmice because of the lowCD3+ T cell numbers.
At sacriﬁce at 12 or 20wkp.i.,weobserved similar distributions
of cell populations in the spleen (Fig. 2E) as in the blood (Fig. 1B) of
uninfected MISTRG and MITRG mice. In infected animals, a
substantial increase in the percentage of splenic CD3+ T cells
compared with uninfected ones was observed in both strains,
particularly inMISTRGmice (8.0265.28%versus58.006 12.54%
CD3+T cells of hCD45+ cells, p = 0.033).We also noted increases in
the activation of CD8+ and CD4+ splenocytes in MISTRGmice, as
well as in MITRG mice, as quantiﬁed by the expression of CD38
and HLA-DR (Fig. 2F, 2G).
Changes in differentiation subsets of CD4+ and CD8+ T cells
in MISTRG mice during acute and chronic HIV infection
HIV infection in humans is divided into three stages: acute HIV
infection (the ﬁrst 12 wk after transmission), chronic HIV
infection, and the late stage, known as AIDS. Similarly, in our
experiments, we deﬁned acute infection as the ﬁrst 12 wk p.i.
FIGURE 2. Sustained HIV infection with CCR5-tropic YU-2 in MISTRG and MITRG mice.
After confirmation of hCD45+ cell (.5% in blood) engraftment, humanized MISTRG and MITRG mice were infected with HIV-1 YU-2. (A) HIV RNA copy
numbers were measured in the plasma over time (MISTRG, n = 6–21; MITRG, n = 4–20). (B) CD3+ T cell percentages, gated on hCD45+ cells, in
peripheral blood shown for MISTRGmice (HIV+ = red circles and HIV2 = gray circles) and MITRG mice (HIV+ = blue squares and HIV2 = gray squares).
Spearman correlation between the percentages of CD4+CD38+HLA-DR+ cells (C) and CD8+CD38+HLA-DR+ cells (D) (of hCD45+ cells) and HIV RNA
copies per milliliter in plasma at 4 wk p.i. (E) Distribution of different cell populations in spleen at sacrifice for uninfected mice (MISTRG, n = 3; MITRG,
n = 9) and infected mice (MISTRG, n = 7; MITRG, n = 6). Frequencies of activated CD8+ T cells (F) and CD4+ T cells (G) (of hCD45+ cells) in spleen. All
data are mean 6 SEM. Statistical differences between groups at different times were calculated using the two-tailed Mann–Whitney U test (A and B)
and the Kruskal–Wallis test with the Dunn multiple-comparison test (E–G). *p , 0.05, **p # 0.01, ***p # 0.001, ****p # 0.0001.
https://doi.org/10.4049/immunohorizons.1700042
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and chronic infection from 12 wk p.i. on (39). Thus, we
sacriﬁced MISTRG mice at 5 and 12–20 wk p.i. to investigate
changes within the T cell compartment in the spleen by ﬂow
cytometry and compared them with age-matched uninfected
MISTRG mice (Fig. 3A).
Within CD4+ splenocytes, we observed a slight increase in
CD45RA+CCR7+ naive T cells (TN) and CD45RA
+CCR72 termi-
nally diﬀerentiated eﬀector memory T cells (TEMRA), whereas
CD45RA2CCR72 eﬀector memory T cells (TEM) and CD45RA
2
CCR7+ central memory T cells (TCM) showed a tendency to de-
crease in infectedMISTRGmice during acute infection compared
with uninfected mice (Fig. 3B). During the chronic phase, we
observed a shift from TEMRA to TEM in the CD4
+ T cell com-
partment, with a concomitant decrease in TN in comparison with
uninfected MISTRG mice.
During the acute phase of infection, TEM and TCM remained
stable among CD8+ T cells, but there was a signiﬁcant increase in
TEMRA and concomitantly lower frequencies of TN (Fig. 3B).
Similar to the CD4+ T cell compartment, we observed a trend for a
shift fromTEMRA toTEMamongCD8
+Tcells (p=0.1175) compared
with uninfected animals.
Notably, the expression of PD-1 is upregulated on terminally
diﬀerentiated T cells after their activation during acute viral
infections (40).Thus,weassessed themedianﬂuorescent intensity
of PD-1 in CD4+ splenocytes, which revealed a diﬀerential ex-
pression (Fig. 3C). The expression of PD-1 was signiﬁcantly
elevated in CD4+ TEMRA; however, it was downregulated during
the acute phase of infection in all other subsets. In the chronic
phase, PD-1 levels onTEMRA remained comparable to those during
acute infection, whereas a substantial increase was observed in
TCM (p = 0.0043) and TEM (p = 0.026).
In CD8+ splenocyte subsets, PD-1 expression was increased on
TN, TCM, and TEMRA (Fig. 3D). A signiﬁcant decrease in PD-1 was
detected on TEM during acute infection. In the chronic phase, only
PD-1 levelsonTEMweresigniﬁcantly increased(p=0.0043) (Fig.3D).
Overall, this dynamic of cellular changes indicated an ongo-
ing immune response upon HIV infection. However, hCD45+
splenocytes isolated from animals during acute infection and
FIGURE 3. Changes in splenic CD4+ and CD8+ T cell subsets during acute and chronic HIV infection in MISTRG mice.
MISTRG mice infected with YU-2 were sacrificed 5 or 12–20 wk p.i., and splenocytes were analyzed for differentiation and PD-1 expression. (A)
Definition of T cell differentiation subsets. (B) Frequency of TN (blue), TEMRA (orange), TCM (pink), and TEM (gray) in CD4
+ and CD8+ T cell subsets in
the spleen during acute infection (upper panel) (MISTRG HIV2, n = 7; HIV+, n = 6) and chronic infection (lower panel) (MISTRG HIV2, n = 6, HIV+,
n = 6). Median fluorescent intensity of PD-1 in uninfected and infected MISTRG mice on CD4+ (C) and CD8+ (D) T cell subsets in acute (upper
panels) and chronic (lower panels) HIV infection. Data are mean 6 SEM. *p , 0.05, **p , 0.01, two-tailed Mann–Whitney U test.
https://doi.org/10.4049/immunohorizons.1700042
166 HIV INFECTION IN MISTRG AND MITRG MICE ImmunoHorizons
 by guest on D
ecem
ber 19, 2017
http://w
w
w
.im
m
unohorizons.org/
D
ow
nloaded from
 
stimulated with Env and Gag HIV peptide pools did not
demonstrate HIV-speciﬁc IFN-g or TNF-a responses (data not
shown).
Sustained HIV NL4-3 infection in MISTRG and
MITRG mice
We also infected MISTRG and MITRG mice with the CXCR4-
tropic strain, NL4-3. Similar to infection with the CCR5-tropic
strain, YU-2, HIV replicationwas higher inMISTRGmice than in
MITRGmice (Fig. 4A). InMISTRGmice, plasmaviral loadsof 3.30
3 1056 1.563 105HIVRNAcopiespermilliliterpeakedat 8wkp.i.
and decreased thereafter, whereas in the MITRG group, viremia
plateaued at 4 wk p.i. with 5.84 3 104 6 3.42 3 104 copies per
milliliter. Remarkably, we could not infect 5 of 12 MITRG mice,
despite reasonable engraftment levels of 11.33 6 1.81% hCD45+
cells in the peripheral blood (data not shown).
The level of CD3+ T cells in the peripheral blood continuously
increased until 8 wk p.i. in MISTRG mice infected with NL4-3,
despite vigorous HIV replication (Fig. 4B); however, this ex-
pansion was lower than in mice infected with YU-2 (Fig. 2B). We
also detected increasing levels of CD3+ T cells in MITRG mice at
12 wk p.i with NL4-3, which was at an earlier time point than in
FIGURE 4. Sustained HIV infection with CXCR4-tropic NL4-3 in MISTRG and MITRG mice.
Analogously to YU-2 infection, mice were infected with 200,000 TCID50 of NL4-3. (A) HIV RNA copy numbers were measured in the plasma in
MISTRG mice (HIV+ = red circles) and MITRG mice (HIV+ = blue squares). (B) Percentages of CD3+ cells in uninfected as well as in HIV-infected
MISTRG and MITRG mice (HIV+ MISTRGmice = red circles; HIV2MISTRGmice = gray circles; HIV+ MITRG mice = blue squares; HIV2MITRGmice =
gray squares). (C and D) Spearman correlation between the percentages of CD4+CD38+HLA-DR+ cells (C) and CD8+CD38+HLA-DR+ cells (D) (of
hCD45+ cells) and HIV RNA copies per milliliter in plasma at 4 wk p.i. (E) Distribution of different cell types in the spleen at euthanasia for uninfected
mice (MISTRG, n = 3; MITRG, n = 9) and infected mice (MISTRG, n = 8; MITRG, n = 3) at 12 and 20 wk p.i. (F) Frequencies of activated CD8+ T cells of
hCD45+ cells in spleen. All data are mean 6 SEM. Statistical differences between groups at different times were calculated by the two-tailed
Mann–Whitney U test (A and B) and the Kruskal–Wallis test with the Dunn multiple-comparison test (E and F). *p , 0.05.
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MITRG mice infected with YU-2. In both infection models, the
CD4+ T cell percentage was lower in infected mice than in the
uninfected control groups, displaying the highly cytopathic nature
of CXCR4-tropic strains (41) (Supplemental Fig. 1).
In accordance with data generated during CCR5-tropic
infection, we detected CD38+HLA-DR+ CD4+ (Fig. 4C) and CD8+
(Fig. 4D) T cells at 4 wk p.i., the percentages of which correlated
with HIV RNA copy numbers in the plasma.
Similar to YU-2 infection, we found more CD3+ T cells in the
spleens of NL4-3–infected MISTRG mice than in uninfected
MISTRG mice (Fig. 4E). In contrast, we did not observe any
increase in T cells in MITRG mice. Cellular subset analysis
revealed more activated CD38+ HLA-DR+ CD8+ splenocytes in
HIV-infected mice than in uninfected ones (Fig. 4F).
No effect of CD8+ T cell depletion on HIV viral load in
MISTRG mice
We observed a tendency for decreasing viral loads after 8 wk p.i.
in MISTRG mice infected with the CCR5- or CXCR4-tropic
strain (Figs. 2A, 4A). We hypothesized that CD8+ T cells were
responsible for this observation. We depleted CD8+ T cells by
administering the anti-humanmAbOKT8 toMISTRGmicebefore
HIV infection. To maintain depletion, we administered OKT8
every 2wk until themicewere sacriﬁced 5wk later. The depletion
was eﬃcient because we did not detect any CD8+ T cells in the
peripheral blood (Fig. 5A). We did not detect diﬀerences in viral
load with or without CD8+ T cells in MISTRG mice (Fig. 5B).
Notably,we observed a trend of a less steep increase in viral load in
CD8+ T cell–depleted animals at 2 wk p.i.; this could be due to an
OKT8-mediated depletion of CD4+CD8+ thymocytes and an
overall decrease in CD3+ T cell levels (Supplemental Fig. 2),
leading to a loss of HIV target cells or the release of chemokines/
cytokines by CD8+ T cells. At the end of the experiment, a signi-
ﬁcant decrease in CD4+ T cell percentage was detected in the
spleens and blood (data not shown) of CD8+ T cell–depleted and
infected MISTRG mice compared with uninfected CD8+ T cell–
depleted animals (Fig. 5C). This probably reﬂects the combined
CD4+ T cell depletion resulting from the reduction of CD4+CD8+
thymocytes by the OKT8 Ab and the destruction of CD4+ T cells
by HIV.
We administeredOKT8 toMITRGmice as well. In contrast to
HIV-infected and CD8+ T cell–depleted MISTRG mice, we
observed a tendency toward a decreased viral load in OKT8-
treated MITRG mice (Supplemental Fig. 3). Similar to OKT8-
treated MISTRG mice, this might be linked to the diminished
CD3+ T cell levels (Supplemental Fig. 3). In addition, MITRG
mice receiving OKT8 showed decreased levels of CD4+ T cells
during infection compared with uninfected controls, suggesting
FIGURE 5. Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG mice.
(A) Depletion protocol: 9-wk-old MISTRG mice were treated on three consecutive days with 50 mg of OKT8 (black arrows), followed by infection
with 200,000 TCID50 of YU-2 (red arrow). Depletion was confirmed in the peripheral blood by flow cytometry at different times (T0, T2, T4, and T5
wk). (B) HIV viral load (MISTRG HIV+, n = 5–10; MISTRG HIV+ OKT8, n = 8–10). (C) CD4+ T cell frequencies in the spleen after sacrifice at 5 wk p.i.
(MISTRG HIV2 [red stippled bar], n = 7; MISTRG HIV+ [red bar], n = 6; MISTRG HIV+ OKT8 [black bar], n = 8; MISTRG HIV2 OKT8 [black stippled bar],
n = 4). **p , 0.01, Kruskal–Wallis test with the Dunn multiple-comparison test. Data are mean 6 SEM. (D) Distribution of different CD4+ T cell
subsets in the spleen at 5 wk p.i. **p , 0.01, two-tailed Mann–Whitney U test.
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CD4+CD8+ thymocyte depletion or HIV-mediated CD4+ T cell
destruction. In addition, we investigated the distribution of CD4+
splenocyte subsets as depicted (Fig. 3A). CD8+ T cell–depleted
uninfected mice showed no signiﬁcant diﬀerences (Fig. 5D) from
untreated uninfected controls (Fig. 3B). Upon YU-2 infection in
depleted animals, a signiﬁcant increase in the TCM compartment
was detected, with concomitant decreases inTN, TEMRA, and TEM
(Fig. 5D) compared with uninfected OKT8-treated MISTRG
mice.
HIV replication profile in MISTRG mice restored in MITRG
mice by phagocytic cell depletion
MITRG and MISTRG are identical mouse strains that diﬀer only
in the expression of human SIRPa. We hypothesized that the
diﬀerences inviral loadandpercentageofCD3+Tcells seenbetween
HIV-infectedMITRG andMISTRGmice are caused by expression
of human SIRPa on murine cells. To simulate a situation free of
phagocytic cells inMITRGmice, and therefore recapitulate some of
the features of MISTRG mice, we administered CLDs to MITRG
mice. Brieﬂy, MITRGmice were treated with CLDs, followed by
YU-2 infection 48 h later (Fig. 6A). The depletionwasmaintained
byrepeatedweekly injectionsofCLDs for3wk.TheCLDprotocol
usedwas very eﬃcient, becausewe did not ﬁnd anymurineCD68
+F4/80+ tissue-resident macrophages in the spleen at euthanasia.
The CLD treatment administered for 3 wk led to a higher blood
engraftment level than the mock treatment (PBS: 12.676 1.82%,
CLD: 30.6564.86%hCD45+ [mean6SEM], p = 0.0221) (Fig. 6B).
The HIV load was three-log higher in CLD-treated mice than in
mock-treated mice (Fig. 6C). The eventual viral load of the CLD
group was even greater than that in HIV-infected MISTRG
mice (Fig. 2A). Remarkably, the depletion of phagocytic cells in
MISTRG mice promoted further HIV replication (Supplemental
Fig. 4).
CLD treatment also resulted in some remarkable cellular
changes in the blood: we observed an increase in NKp46+ cells in
HIV-infectedMITRGmice (Fig.6D).Similar topreviouslyobserved
increases in activated CD4+ and CD8+ T cells in YU-2–infected
MISTRGmice,we detected elevated levels inCLD-treatedMITRG
mice (Fig. 6E).However,wedidnot detect activatedTcells inCLD-
treated MISTRGmice (Supplemental Fig. 4).
Human cell engraftmentwas substantially elevated, up to;40%
of hCD45+ cells, in spleens of CLD-treated MITRG mice (Fig. 6F).
Splenic cell distributions resembled those in the peripheral blood of
MISTRG mice at 9 wk of age (Fig. 1B). Signiﬁcantly, more CD3+
splenocytes were observed in uninfected and infected CLD-treated
MITRG mice than in PBS control mice. Furthermore, we found a
signiﬁcant increase in human CD68+CD1632 and CD68+CD163+
splenic macrophages in CLD-treated mice, irrespective of HIV
infection (PBS p = 0.008) (Fig. 6F). Moreover, HIV infection alone
appeared to induce expansion of CD68+CD163+ macrophages.
Taken together, the depletion ofmacrophages inMITRGmice
reproduced, in essence, the data observed in MISTRG mice and
supports our hypothesis that the expression of human SIRPa on
murine macrophages is at the origin of the diﬀerences observed
between HIV-infected humanized MITRG andMISTRG mice.
DISCUSSION
In this study, our main ﬁndings were that, even without pre-
conditioning, we obtained eﬃcient engraftment levels in MI(S)
TRG mice; reconstituted MITRG and MISTRG mice are suscep-
tible to HIV infection with distinct coreceptor selectivity, and the
infection is sustained over 20 wk; MITRG mice show a diﬀerent
patternofHIV infectioncomparedwithMISTRGmice, in termsof
lowerHIVreplicationandTcell levels; theHIV-replicationproﬁle
in MISTRG mice is restored in MITRG mice by depleting
phagocytic cells, resulting in increased viral loads and higher
engraftment levels; and CD8+ T cell depletion in HIV-infected
MISTRG mice induces massive CD4+ T cell depletion but has
no eﬀect on HIV replication rate. Clodronate treatment removes
the negative regulation of xenogenic murine macrophages on
human hematopoiesis and allows a faster HIV pathogenesis; thus,
the similar HIV-replication pattern in HIV-infected MISTRG
miceandmacrophage-depletedMITRGmicepoints toaparticular
role for SIRPa in these HIV models. Overall, both models are
suitable for the study of the interplay between the immune system
and HIV.
Irradiation of MISTRG mice promotes liberation of space in
the bone marrow niche for injected human CD34+ cells, and high
levels of multilineage human hematopoiesis are supported by the
knock-in of human cytokines. This, in turn, may result in severe
anemia and limited experimentation and lifespan (24). Similar
observations were made in MIS(KI)TRGmice (42), a novel mouse
model similar to MISTRG mice that expresses the human SIRPa
from the correspondingmouse locus instead of a bacterial artiﬁcial
chromosome transgene. Thus, we transplanted newborn mice
without any preconditioningwith cord bloodHSPCs and obtained
slightly lower engraftment levels at 9 wk of age than in irradiated
animals transplanted with fetal liver–derived HSPCs (24).
However, we observed that human peripheral cells waned at
;36wk of age. Furthermore,MITRG/MISTRGmice also support
engraftment with mobilized peripheral blood CD34+ cells from
adults (43). Thus, MITRG/MISTRGmice support engraftment of
any kind of CD34+ cells, with more prominent engraftment if
irradiated prior to transplantation.
Reconstituted MISTRG and MITRG mice showed sustained
and robust HIV replication of the CCR5-tropic strain, YU-2, and
the CXCR4-tropic strain, NL4-3, over 20 wk (44). This HIV
replication was paralleled by an expansion of the CD3+ T cell
population in HIV-infectedmice; indeed, in the YU-2–infected
MISTRG mice, we even observed an initial expansion of
CD4+ T cells, followed by a decline, reminiscent of HIV in-
fection in humans. However, we are challenged by the para-
doxical waning of human CD3+ T cells over time in uninfected
mice. Thus, HIV appears to be a transient stimulus for the
human graft. The constellation observed might be due to a less
eﬃcient engraftment in mice without preconditioning com-
pared with mice with preconditioning. Notably, reconstitution
without preconditioning results in limited lifetime of the
human graft (45).
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FIGURE 6. Clodronate-mediated mononuclear phagocytic cell depletion induces HIV-replication profile of MISTRG in MITRG mice and
elevates viral load levels.
(A) Depletion protocol: 9-wk-old MITRG mice were treated with 1 mg of CLDs per 20 g body weight (black arrows), followed by infection with YU-2
(red arrow). Thereafter, the depletion was maintained once weekly, with 0.5 mg per 20 g body weight of CLDs. Depletion was confirmed at the end
of the experiment in the spleen by staining for murine tissue-resident macrophages. (B) Percentage of hCD45+ cells in the blood at 2 wk p.i.;
uninfected mice were pooled with infected mice (PBS, n = 10; CLD, n = 20). (C) HIV viral load in CLD-treated (n = 9–11) and PBS-treated (n = 6) MITRG
mice. (D) NKp46+ cells, as the percentage of hCD45+ cells, in peripheral blood. (E) Frequency of activated CD4+ and CD8+ T cells (Continued)
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We found an increase in CD4+ and CD8+ TEMRA 5 wk p.i.,
pointing to an immune response against HIV concomitant with a
decrease in CD4+ TEM, an HIV target in early infection (46).
During the chronic phase, we observed a signiﬁcant increase in
TEMpopulations.This ismost likely explainedbyaTCMpopulation
capable of continuous high-level production of new TEM (46).
Comparing the T cell population in the acute versus chronic
phases of HIV infection, we observed a prominent contraction of
CD4+ TN, whereas the TEM population expanded, in the chronic
phase; the contraction/expansion of CD4+ T cell subsets that we
observed was similar to that observed in HIV-infected NSG mice
(30). Notably, the distribution of splenic T cell subsets in un-
infectedMISTRGmice resembled that of reconstitutedNSGmice
(47) and of healthy humans (48). During acute infection, TEMRA
were positive for PD-1 expression, which is a regulator of T cell
activation (49) and a marker of exhaustion during viral infections
(50, 51). The expression of PD-1 in humice was reminiscent of the
ﬁndings in humans suﬀering from acute HIV infection (44, 52).
However, at the later stage of infection, an increase in PD-1 levels
was also observed onCD4+ TCM andTEM, aswell as on CD8
+ TEM,
resembling the ﬁndings in individuals in chronic stages of HIV
infection
We detected activated CD4+ and CD8+ T cells by means of
coexpression of HLA-DR and CD38 in MISTRG mice infected
with YU-2. This represents one of the major hallmarks of HIV
infection (53–55). The frequencies of activated CD4+ and CD8+
T cells correlated with HIV RNA copy numbers, in line with
ﬁndings in HIV-infected humans (54). We found lower CD4+
T cell levels during NL4-3 infection, which is explained by the
highly cytopathic eﬀect of this virus strain (41, 56). These ﬁndings
were conﬁrmed by analyzing the cell-activation pattern in the
spleen of HIV-infected MISTRG mice, where we found sub-
stantially higher frequencies of activated CD8+ splenocytes.
Therefore, these two novel humanized mouse models mirror
some of the key aspects of acute and chronic HIV infection.
Strikingly, we observed a one-log diﬀerence in HIV viral load
between MISTRG and MITRG mice, which was apparent at 4–8
wk p.i. and persisted throughout the acute phase. MISTRG mice
diﬀer from MITRG mice solely by the transgenic expression of
the human don’t-eat-me signal, SIRPa. We hypothesized that this
signal prevents the clearance of human lymphoid cells, which
primarily express CD47, and thereby, promotes the expansion of
the pool of potential HIV target cells. Itmight also prevent the loss
ofHIV-infected cells. Indeed,MISTRGmice, unlikeMITRGmice,
showed a progressive increase in CD3+ T cell levels. Thus, we
further hypothesized thatwe can revert thisproﬁle by depletionof
murine macrophages in MITRG mice. We used CLDs to deplete
themononuclear phagocytic cells and found that CLDs selectively
aﬀected the mouse tissue-resident macrophages that develop
during embryogenesis (57). In concordance with previous studies
(58, 59), the depletion resulted in substantially higher engraftment
levels and, indeed, in substantially higher viral loads. Thus, we
obtained an HIV-replication proﬁle in MITRG mice resembling
MISTRG mice by preventing macrophage-mediated engulfment
of human cells with CLDs. In addition to the overall enhanced
engraftment levels, depletion of tissue-resident macrophages
resulted in elevated levels of NKp46+ cells in the blood at early
time points of infection that we did not observe previously in any
other experiment. Human CD68+CD163+ and CD68+CD1632
macrophages, which most likely have a monocytic origin, were
also increased in CLD-treated MITRG mice. We explain the
elevated macrophage reconstitution by the overall elevated levels
of myeloid cells. We also observed a tendency for increased
frequencies of CD68+CD163+ macrophages in CLD-treated and
YU-2–infected animals. Similar observations were reported dur-
ing SIV infection (60, 61), and soluble CD163 has been suggested
as a biomarker for attempts of the immune system to resolve
immuneactivation inducedbyHIV (62). Thus, data obtainedusing
macrophage-depletedhumanizedMITRGmice are reminiscentof
the data in MISTRG mice and point to a central role for SIRPa
expression on macrophages in MISTRG mice for the phenotype
observed. The exact role of SIRPa in HIV pathogenesis remains
to be determined.
In addition,CLD treatment revealed the sameelevation inviral
load inMISTRGmice as inMITRGmice, without any increase in
engraftment or target cells, excluding an eﬀect related to the
proportional amount of target cells. Our observation might be ex-
plained by the fact thatMISTRGmice express human andmurine
SIRPa, and a residual phagocytic activity by murine macrophages
cannot be excluded. Human macrophages appear to be infected
by engulfed HIV-infected CD4+ T cells, which leads to sub-
stantially elevated HIV RNA levels in vitro (63).
We also compared the HIV-replication rate of MISTRG/
MITRG mice with other humanized mouse models that we used
over the years (26, 35, 64, 65). Advantageously, we have been using
the identical infectionprocedureandeven the sameR5-tropicHIV
strain, YU-2. In fact, the extent of HIV replicationwas the same in
MISTRGmice as in hu Rag22/2gc2/2, NOG, and NSGmice; all of
these latterhumicehadadistinctoverall engraftment level (20.56
22.3, 20.7 6 13.2, and 48.8 6 16.7% [average 6 SD], respectively,
hCD45+ cells of all viable mononucleated cells) that points to
factors other than the engraftment level determining the viral-
replication rate. The MITRG mice set themselves apart with
their one-log lower viral-replication rate, especially in compar-
ison with MISTRG mice.
After the initial viral peak,MISTRGmice exhibited a constant
decrease in viral burdenandchanges in thememory/eﬀectorTcell
compartments over time. To assess the contribution of CD8+
T cells, we depleted them before HIV infection. Unexpectedly, we
did not see any increase in viral load in HIV-infected MISTRG
in blood. (F) Percentage of hCD45+ cells (left panel), distribution of different cell types (middle panel), and frequency of macrophage subsets (right
panel) in the spleen. Error bars indicate SEM. *p # 0.05, **p # 0.01, ***p # 0.001, ****p # 0.0001, two-tailed Mann–Whitney U test (B–D),
Kruskal–Wallis test (E and F).
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mice, negating a potential CD8+ T cell–driven antiviral eﬀect.
These data are in line with a previous study that also found that
depletion of CD8+ T cells prior to HIV infection had no eﬀect on
lowering HIV (66); in that study, the investigators concluded that
acute HIV replication in humanized NSG mice is primarily
constrained by the number of available targets in lymphoid tissue
rather than by CD8+ T cells. In our hands, however, there were
substantially fewer CD4+ T cells in the spleen of depleted and
infected animals than in depleted and HIV2MISTRG mice, and
there was a tendency for increased CD4+ T cell levels in infected
and undepleted MISTRG mice. This constellation is consistent
with a role for CD8+ T cells in preventing CD4+ T cell loss early
during HIV infection in CD34+-reconstituted MISTRG mice.
Alternatively, we have to consider that the latter ﬁnding is strictly
due to a depletionofCD4+CD8+ double-positive thymocytes,with
subsequent reducedCD4+ T cell reconstitution. In contrast to the
above-discussed ﬁndings, HIV-speciﬁc CD8+ T cells are present
in chronically HIV-infected NSG mice, and their depletion at
this later time point resulted in an increase in viral load (67).
In addition, we did not detect any human HIV-speciﬁc IgG at
12 and 20 wk p.i., consistent with published data (68). The lack of
humanHIV-speciﬁcIgGis largelyexplainedby thepredominanceof
immature B cells (24). However, some improvement could be
achievedby cotransplantinghuman fetal liver and thymic tissue (69)
or the expression of IL-6 (70, 71). These approacheswould probably
also result in elevated frequencies of HIV-speciﬁc T cells. Another
limitation was the observation of anemia mainly in MISTRG mice
related to high engraftment and leading to their exclusion from
experiments, althoughwedidnot irradiate them.Asolutionmightbe
touse fewerHSPCs for transplantation,withpossible impairment in
engraftment. Notably, we did not observe graft-versus-host disease,
which is regularly seen in humanized NSG mice (72), at any time
point.
In summary, MITRG and MISTRG mice support HIV repli-
cation. Because of superior development of myeloid cells com-
pared with existing humanized mouse models, this model oﬀers
the opportunity to study innate immune system modulators (73,
74) and PD-1 inhibitors (75, 76) as treatment for HIV infection. In
addition, the roles of CD47 and SIRPa could be studied during
infection inMISTRGmice, because the role of this interaction has
not yet been deﬁned for HIV, in contrast to cancer and diﬀerent
infectious diseases (77–79). Furthermore, MISTRG mice mirror
key features of HIV infection and oﬀer a favorable model to study
the various myeloid cell types involved in HIV infection.
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